Literature DB >> 23178462

Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.

Li-xia Dong1, Lin-lin Sun, Xia Zhang, Li Pan, Lin-juan Lian, Zhe Chen, Dian-sheng Zhong.   

Abstract

AIM: To investigate the role of LKB1 in regulation of mTOR signaling in non-small cell lung cancer (NSCLC) cells.
METHODS: LKB1 protein expression and phosphorylation of AMPK, 4E-BP1 and S6K in the cells were assessed using Western blotting in various NSCLC cell lines (A549, H460, H1792, Calu-1 and H1299). Energy stress was mimicked by treating the cells with 2-deoxyglucose (2-DG). Compound C was used to inhibit AMPK activity. Cell growth was measured using the MTS assay.
RESULTS: LKB1 protein was expressed in LKB1 wild-type Calu-1, H1299 and H1792 cells, but it was undetected in LKB1 mutant A549 and H460 cells. Treatment of the LKB1 wild-type cells with 2-DG (5, 10 and 25 mmol/L) augmented the phosphorylation of AMPK in dose- and time-dependent manners. In the LKB1 wild-type cells, 2-DG dramatically suppressed the phosphorylation of two mTOR targets, 4E-BP1 and S6K, whereas the LKB1 mutant A549 and H460 cells were highly resistant to 2-DG-induced inhibition on mTOR activity. In addition, stable knockdown of LKB1 in H1299 cells impaired 2-DG-induced inhibition on mTOR activity. Pretreatment of H1299 and H1792 cells with the AMPK inhibitor compound C (10 μmol/L) blocked 2-DG-induced inhibition on mTOR activity. 2-DG inhibited the growth of H1299 cells more effectively than that of H460 cells; stable knockdown of LKB1 in H1299 cells attenuated the growth inhibition caused by 2-DG.
CONCLUSION: In non-small cell lung cancer cells, LKB1/AMPK signaling negatively regulates mTOR activity and contributes to cell growth inhibition in response to energy stress.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178462      PMCID: PMC4011621          DOI: 10.1038/aps.2012.143

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  22 in total

1.  Establishment and gene expression profiling of LKB1 stable knockdown lung cancer cell line.

Authors:  Lin-lin Sun; Dian-sheng Zhong; Song Wu; Hua Bai; Zhe Chen
Journal:  Chin Med J (Engl)       Date:  2011-07-05       Impact factor: 2.628

2.  Very high risk of cancer in familial Peutz-Jeghers syndrome.

Authors:  F M Giardiello; J D Brensinger; A C Tersmette; S N Goodman; G M Petersen; S V Booker; M Cruz-Correa; J A Offerhaus
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

3.  A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.

Authors:  A Hemminki; D Markie; I Tomlinson; E Avizienyte; S Roth; A Loukola; G Bignell; W Warren; M Aminoff; P Höglund; H Järvinen; P Kristo; K Pelin; M Ridanpää; R Salovaara; T Toro; W Bodmer; S Olschwang; A S Olsen; M R Stratton; A de la Chapelle; L A Aaltonen
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

4.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

5.  The LKB1 tumor suppressor negatively regulates mTOR signaling.

Authors:  Reuben J Shaw; Nabeel Bardeesy; Brendan D Manning; Lyle Lopez; Monica Kosmatka; Ronald A DePinho; Lewis C Cantley
Journal:  Cancer Cell       Date:  2004-07       Impact factor: 31.743

6.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

Authors:  Montserrat Sanchez-Cespedes; Paola Parrella; Manel Esteller; Shuji Nomoto; Barry Trink; James M Engles; William H Westra; James G Herman; David Sidransky
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

7.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.

Authors:  Michael N Corradetti; Ken Inoki; Nabeel Bardeesy; Ronald A DePinho; Kun-Liang Guan
Journal:  Genes Dev       Date:  2004-07-01       Impact factor: 11.361

8.  LKB1 is the upstream kinase in the AMP-activated protein kinase cascade.

Authors:  Angela Woods; Stephen R Johnstone; Kristina Dickerson; Fiona C Leiper; Lee G D Fryer; Dietbert Neumann; Uwe Schlattner; Theo Wallimann; Marian Carlson; David Carling
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

9.  Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.

Authors:  Simon A Hawley; Jérôme Boudeau; Jennifer L Reid; Kirsty J Mustard; Lina Udd; Tomi P Mäkelä; Dario R Alessi; D Grahame Hardie
Journal:  J Biol       Date:  2003-09-24

10.  Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome.

Authors:  W Lim; N Hearle; B Shah; V Murday; S V Hodgson; A Lucassen; D Eccles; I Talbot; K Neale; A G Lim; J O'Donohue; A Donaldson; R C Macdonald; I D Young; M H Robinson; P W R Lee; B J Stoodley; I Tomlinson; D Alderson; A G Holbrook; S Vyas; E T Swarbrick; A A M Lewis; R K S Phillips; R S Houlston
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more
  14 in total

1.  The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.

Authors:  Jeanine L Van Nostrand; Alice Brisac; Stephano S Mello; Suzanne B R Jacobs; Richard Luong; Laura D Attardi
Journal:  Cancer Discov       Date:  2015-03-26       Impact factor: 39.397

Review 2.  Autophagy-related signaling pathways in non-small cell lung cancer.

Authors:  Jing Wang; Mei Gong; Xirong Fan; Dalu Huang; Jinshu Zhang; Cheng Huang
Journal:  Mol Cell Biochem       Date:  2021-11-10       Impact factor: 3.396

3.  Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis.

Authors:  Ajaib S Paintlia; Sarumathi Mohan; Inderjit Singh
Journal:  J Clin Cell Immunol       Date:  2013-06-30

4.  Liver kinase B1/adenosine monophosphate-activated protein kinase signaling axis induces p21/WAF1 expression in a p53-dependent manner.

Authors:  Qing Ma; Ping Xiao; Linlin Sun; Jing Wang; Diansheng Zhong
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

5.  Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.

Authors:  Rafaela Andrade-Vieira; Donna Goguen; Heidi A Bentley; Chris V Bowen; Paola A Marignani
Journal:  Oncotarget       Date:  2014-12-30

6.  TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.

Authors:  Ying Xing; Qingwei Meng; Xuesong Chen; Yanbin Zhao; Wei Liu; Jing Hu; Feng Xue; Xiaoyuan Wang; Li Cai
Journal:  Oncotarget       Date:  2016-05-24

7.  2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells.

Authors:  Linlin Sun; Xiuju Liu; Haian Fu; Wei Zhou; Diansheng Zhong
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

8.  Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy.

Authors:  Inyoung Kim; Yu-Ying He
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244

Review 9.  Activation of mTOR: a culprit of Alzheimer's disease?

Authors:  Zhiyou Cai; Guanghui Chen; Wenbo He; Ming Xiao; Liang-Jun Yan
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-09       Impact factor: 2.570

10.  AMP-Activated Protein Kinase Signalling in Cancer and Cardiac Hypertrophy.

Authors:  Yulia Lipovka; John P Konhilas
Journal:  Cardiovasc Pharm Open Access       Date:  2015-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.